CAR-T therapy development has achieved big success over the past years with regulatory approval by the FDA for blood cancer treatment. In this workshop, experts from the industry will be assembled to discuss the development and implementation of this therapy. Their topics will cover several key aspects of the CAR-T industry chain, from discovery, manufacture to commercialization.
[/fusion_code]
Speaker 1: Allison Montalvo, Executive Director, Head of Project Management and Clinical Supply, Tmunity Therapeutics
Topic: CAR-T CMC management: how to streamline drug development, manufacturing and logistics (Tentative)
Speaker 2: Fang Chen, Senior Research Investigator, Center for Cellular Immunotherapies (CCI), University of Pennsylvania
Topic: Engineered T Cell Therapies From a Drug Development Viewpoint
Speaker 3: Teng Peng, Application Support Manager, ACROBiosystems
Topic: The Applications of ACROBiosystem’s Products in CAR-T Cell Therapeutics
Speaker 4: Levi Gray-Rupp, Associate Director, CAR-T/iPSC, Janssen
Topic: Leveraging synthetic biology to enhance CAR-T safety and efficacy
[/fusion_code]
Speaker 1: Allison Montalvo, Executive Director, Head of Project Management and Clinical Supply, Tmunity Therapeutics
Topic: CAR-T CMC management: how to streamline drug development, manufacturing and logistics (Tentative)
Speaker 2: Fang Chen, Senior Research Investigator, Center for Cellular Immunotherapies (CCI), University of Pennsylvania
Topic: Engineered T Cell Therapies From a Drug Development Viewpoint
Speaker 3: Teng Peng, Application Support Manager, ACROBiosystems
Topic: The Applications of ACROBiosystem’s Products in CAR-T Cell Therapeutics
Speaker 4: Levi Gray-Rupp, Associate Director, CAR-T/iPSC, Janssen
Topic: Leveraging synthetic biology to enhance CAR-T safety and efficacy
[/fusion_code]
Speaker 1: Allison Montalvo, Executive Director, Head of Project Management and Clinical Supply, Tmunity Therapeutics
Topic: CAR-T CMC management: how to streamline drug development, manufacturing and logistics (Tentative)
Speaker 2: Fang Chen, Senior Research Investigator, Center for Cellular Immunotherapies (CCI), University of Pennsylvania
Topic: Engineered T Cell Therapies From a Drug Development Viewpoint
Speaker 3: Teng Peng, Application Support Manager, ACROBiosystems
Topic: The Applications of ACROBiosystem’s Products in CAR-T Cell Therapeutics
Speaker 4: Levi Gray-Rupp, Associate Director, CAR-T/iPSC, Janssen
Topic: Leveraging synthetic biology to enhance CAR-T safety and efficacy